Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$32.26
At close: May 29 EDT
$33.50
1.243.84%
Pre-Market: 4:11 AM EDT
Comments
Loading...
BridgeBio Pharma Analyst Ratings and Price Targets | NASDAQ:BBIO | Benzinga
BridgeBio Pharma Inc has a consensus price target of $49.11 based on the ratings of 21 analysts. The high is $95 issued by Cantor Fitzgerald on February 21, 2025. The low is $19 issued by SVB Leerink on January 23, 2023. The 3 most-recent analyst ratings were released by Scotiabank, Piper Sandler, and UBS on April 30, 2025, respectively. With an average price target of $63.33 between Scotiabank, Piper Sandler, and UBS, there's an implied 89.05% upside for BridgeBio Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
Piper Sandler
UBS
HC Wainwright & Co.
Redburn Atlantic
1calculated from analyst ratings
Analyst Ratings for BridgeBio Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/30/2025 | Buy Now | 64.18% | Scotiabank | Greg Harrison49% | $52 → $55 | Maintains | Sector Outperform | Get Alert |
| 04/30/2025 | Buy Now | 88.06% | Piper Sandler | Biren Amin39% | $46 → $63 | Maintains | Overweight | Get Alert |
| 04/30/2025 | Buy Now | 114.93% | UBS | Eliana Merle43% | $65 → $72 | Maintains | Buy | Get Alert |
| 04/15/2025 | Buy Now | 58.21% | HC Wainwright & Co. | Raghuram Selvaraju42% | $49 → $53 | Maintains | Buy | Get Alert |
| 03/31/2025 | Buy Now | 49.25% | Redburn Atlantic | Joshua Smith 37% | → $50 | Initiates | → Buy | Get Alert |
| 03/24/2025 | Buy Now | 49.25% | JP Morgan | Anupam Rama56% | $44 → $50 | Maintains | Overweight | Get Alert |
| 02/21/2025 | Buy Now | 46.27% | Citigroup | David Lebowitz53% | $45 → $49 | Maintains | Buy | Get Alert |
| 02/21/2025 | Buy Now | 183.58% | Cantor Fitzgerald | Josh Schimmer52% | $95 → $95 | Reiterates | Overweight → Overweight | Get Alert |
| 02/21/2025 | Buy Now | 55.22% | Scotiabank | Greg Harrison49% | $49 → $52 | Maintains | Sector Outperform | Get Alert |
| 02/13/2025 | Buy Now | 46.27% | HC Wainwright & Co. | Raghuram Selvaraju42% | $49 → $49 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | 46.27% | Scotiabank | Greg Harrison49% | $48 → $49 | Maintains | Sector Outperform | Get Alert |
| 12/23/2024 | Buy Now | 49.25% | Evercore ISI Group | Cory Kasimov68% | $45 → $50 | Maintains | Outperform | Get Alert |
| 12/16/2024 | Buy Now | 46.27% | HC Wainwright & Co. | Raghuram Selvaraju42% | $49 → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | 43.28% | Scotiabank | Greg Harrison49% | $45 → $48 | Maintains | Sector Outperform | Get Alert |
| 11/25/2024 | Buy Now | 34.33% | B of A Securities | Geoff Meacham61% | $42 → $45 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 46.27% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $49 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | 34.33% | Scotiabank | Greg Harrison49% | $44 → $45 | Maintains | Sector Outperform | Get Alert |
| 10/25/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2024 | Buy Now | 37.31% | Leerink Partners | Mani Foroohar47% | $47 → $46 | Maintains | Outperform | Get Alert |
| 10/16/2024 | Buy Now | 31.34% | Scotiabank | Greg Harrison49% | → $44 | Initiates | → Sector Outperform | Get Alert |
| 10/03/2024 | Buy Now | — | Oppenheimer | Leland Gershell67% | — | Initiates | → Perform | Get Alert |
| 10/02/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/30/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 108.96% | Cantor Fitzgerald | Josh Schimmer52% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | 25.37% | B of A Securities | Geoff Meacham61% | $42 → $42 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 108.96% | Cantor Fitzgerald | Josh Schimmer52% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 09/04/2024 | Buy Now | 37.31% | Piper Sandler | Biren Amin39% | → $46 | Initiates | → Overweight | Get Alert |
| 09/03/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/27/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 28.36% | JP Morgan | Anupam Rama56% | $46 → $43 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 34.33% | Evercore ISI Group | Cory Kasimov68% | $50 → $45 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 07/01/2024 | Buy Now | 108.96% | Cantor Fitzgerald | Josh Schimmer52% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 06/25/2024 | Buy Now | 25.37% | B of A Securities | Geoff Meacham61% | $50 → $42 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $43 → $43 | Reiterates | Buy → Buy | Get Alert |
| 05/28/2024 | Buy Now | 108.96% | Cantor Fitzgerald | Josh Schimmer52% | $70 → $70 | Reiterates | Overweight → Overweight | Get Alert |
| 05/28/2024 | Buy Now | 40.3% | UBS | Eliana Merle43% | $51 → $47 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 28.36% | HC Wainwright & Co. | Raghuram Selvaraju42% | $47 → $43 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 49.25% | Evercore ISI Group | Cory Kasimov68% | → $50 | Initiates | → Outperform | Get Alert |
| 03/20/2024 | Buy Now | 34.33% | JP Morgan | Anupam Rama56% | $35 → $45 | Maintains | Overweight | Get Alert |
| 03/19/2024 | Buy Now | 108.96% | Cantor Fitzgerald | Josh Schimmer52% | $60 → $70 | Maintains | Overweight | Get Alert |
| 03/11/2024 | Buy Now | 79.1% | Cantor Fitzgerald | Josh Schimmer52% | $50 → $60 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 58.21% | Mizuho | Salim Syed43% | $60 → $53 | Maintains | Buy | Get Alert |
| 03/04/2024 | Buy Now | 40.3% | HC Wainwright & Co. | Raghuram Selvaraju42% | $47 → $47 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 37.31% | Citigroup | David Lebowitz53% | $42 → $46 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 10.45% | BMO Capital | Kostas Biliouris34% | → $37 | Initiates | → Market Perform | Get Alert |
| 01/29/2024 | Buy Now | 40.3% | HC Wainwright & Co. | Raghuram Selvaraju42% | $22 → $47 | Maintains | Buy | Get Alert |
| 01/22/2024 | Buy Now | 49.25% | Cantor Fitzgerald | Josh Schimmer52% | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 25.37% | Citigroup | David Lebowitz53% | → $42 | Initiates | → Buy | Get Alert |
| 10/24/2023 | Buy Now | 49.25% | Cantor Fitzgerald | Josh Schimmer52% | → $50 | Initiates | → Overweight | Get Alert |
| 08/28/2023 | Buy Now | 79.1% | Mizuho | Salim Syed43% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | Buy Now | 13.43% | JP Morgan | Anupam Rama56% | $42 → $38 | Maintains | Overweight | Get Alert |
| 08/14/2023 | Buy Now | 79.1% | Mizuho | Salim Syed43% | $50 → $60 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 49.25% | Goldman Sachs | Paul Choi58% | $29 → $50 | Maintains | Buy | Get Alert |
| 07/18/2023 | Buy Now | 37.31% | Raymond James | Dane Leone45% | $29 → $46 | Maintains | Outperform | Get Alert |
| 07/18/2023 | Buy Now | -1.49% | Jefferies | Eun Yang33% | $24 → $33 | Downgrade | Buy → Hold | Get Alert |
| 05/08/2023 | Buy Now | -13.43% | Mizuho | Salim Syed43% | $23 → $29 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 19.4% | Evercore ISI Group | Josh Schimmer52% | → $40 | Initiates | → Outperform | Get Alert |
| 04/13/2023 | Buy Now | -19.4% | SVB Securities | Mani Foroohar47% | $25 → $27 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | -31.34% | JP Morgan | Anupam Rama56% | $18 → $23 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | -16.42% | Goldman Sachs | Paul Choi58% | $20 → $28 | Maintains | Buy | Get Alert |
| 03/07/2023 | Buy Now | -13.43% | Raymond James | Dane Leone45% | $17 → $29 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren45% | — | Initiates | → Outperform | Get Alert |
| 01/23/2023 | Buy Now | -43.28% | SVB Leerink | Mani Foroohar47% | $23 → $19 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | -43.28% | JP Morgan | Anupam Rama56% | $20 → $19 | Maintains | Overweight | Get Alert |
| 08/24/2022 | Buy Now | -31.34% | Mizuho | Salim Syed43% | $25 → $23 | Maintains | Buy | Get Alert |
| 07/26/2022 | Buy Now | -10.45% | SVB Leerink | Mani Foroohar47% | $27 → $30 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for BridgeBio Pharma (BBIO) stock?
The latest price target for BridgeBio Pharma (NASDAQ:BBIO) was reported by Scotiabank on April 30, 2025. The analyst firm set a price target for $55.00 expecting BBIO to rise to within 12 months (a possible 64.18% upside). 40 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
The latest analyst rating for BridgeBio Pharma (NASDAQ:BBIO) was provided by Scotiabank, and BridgeBio Pharma maintained their sector outperform rating.
When was the last upgrade for BridgeBio Pharma (BBIO)?
There is no last upgrade for BridgeBio Pharma
When was the last downgrade for BridgeBio Pharma (BBIO)?
The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $52.00 to $55.00. The current price BridgeBio Pharma (BBIO) is trading at is $33.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
